Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease

被引:40
作者
Bucolo, Claudio [1 ,2 ]
Fidilio, Annamaria [1 ]
Fresta, Claudia Giuseppina [1 ]
Lazzara, Francesca [1 ]
Platania, Chiara Bianca Maria [1 ]
Cantarella, Giuseppina [1 ]
Di Benedetto, Giulia [1 ]
Burgaletto, Chiara [1 ]
Bernardini, Renato [1 ]
Piazza, Cateno [3 ]
Barabino, Stefano [4 ]
Drago, Filippo [1 ,2 ]
机构
[1] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy
[3] Univ Catania Consortium Unifarm, Analyt Dept, Catania, Italy
[4] Univ Milan, Ocular Surface & Dry Eye Ctr, Osped L Sacco, Milan, Italy
关键词
dry eye disease; inflammation; cornea; hydrocortisone; Sjogren syndrome; NF-KAPPA-B; TEAR FILM; TRAIL; CORTICOSTEROIDS; PROLIFERATION; MODELS; ROLES; TESTS; CELLS;
D O I
10.3389/fphar.2019.01240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the ocular pharmacological profile of hydrocortisone (HC) using in vitro and in vivo models of dry eye disease. Rabbit corneal epithelial cells (SIRCs) were used to assess the effect of HC in two paradigms of corneal damage: hyperosmotic stress and scratch-wound assay. Dry eye was induced in albino rabbits by topical administration of atropine sulfate or by injection of concanavalin A (ConA) into the lacrimal gland. TNF alpha, TNF-related apoptosis-inducing ligand (TRAIL), IL-1 beta, and IL-8 were determined by ELISA or western blot in a corneal damage hyperosmotic in vitro model, with or without HC treatment. Inflammatory biomarkers, such as TNF alpha, IL-8, and MMP-9, were evaluated in tears of rabbit eye injected with ConA and treated with HC. Tear volume and tear film integrity, in both in vivo models, were evaluated by the Schirmer test and tear break-up time (TBUT). Ocular distribution of four formulations containing HC (0.001%, 0.003%, 0.005%, and 0.33%) was performed in the rabbit eye. Aqueous humor samples were collected after 15, 30, 60, and 90 min from instillation and then detected by LC-MS/MS. Hyperosmotic insult significantly activated protein expression of inflammatory biomarkers, which were significantly modulated by HC treatment. HC significantly enhanced the re-epithelialization of scratched SIRCs. Treatment with HC eye drops significantly reduced the tear concentrations of TNF-alpha, IL-8, and MMP-9 vs. vehicle in the ConA dry eye model. Moreover, HC significantly restored the tear volume and tear film integrity to levels of the control eyes, both in ConA- and atropine-induced dry eye paradigms. Finally, we demonstrated that HC crossed, in a dose-dependent manner, the corneal barrier when the eyes were topically treated with HC formulations (dose range 0.003-0.33%). No trace of HC was detected in the aqueous humor after ocular administration of eye drops containing the lowest dose of the drug (0.001%), indicating that, at this very low concentration, the drug did not pass the corneal barrier avoiding potential side effects such as intraocular pressure rise. Altogether, these data suggest that HC, at very low concentrations, has an important anti-inflammatory effect both in vitro and in vivo dry eye paradigms and a good safety profile.
引用
收藏
页数:9
相关论文
共 35 条
[1]   Management of postoperative inflammation after cataract and complex ocular surgeries: a systematic review and Delphi survey [J].
Aptel, Florent ;
Colin, Cyrille ;
Kaderli, Sema ;
Deloche, Catherine ;
Bron, Alain M. ;
Stewart, Michael W. ;
Chiquet, Christophe .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (11) :1-10
[2]   Tear film and ocular surface tests in animal models of dry eye: uses and limitations [J].
Barabino, S ;
Chen, W ;
Dana, MR .
EXPERIMENTAL EYE RESEARCH, 2004, 79 (05) :613-621
[3]   Checks and balances: The glucocorticoid receptor and NFκB in good times and bad [J].
Bekhbat, Mandakh ;
Rowson, Sydney A. ;
Neigh, Gretchen N. .
FRONTIERS IN NEUROENDOCRINOLOGY, 2017, 46 :15-31
[4]   TFOS DEWS II pathophysiology report [J].
Bron, Anthony J. ;
de Paiva, Cintia S. ;
Chauhan, Sunil K. ;
Bonini, Stefano ;
Gabison, Eric E. ;
Jain, Sandeep ;
Knop, Erich ;
Markoulli, Maria ;
Ogawa, Yoko ;
Perez, Victor ;
Uchino, Yuichi ;
Yokoi, Norihiko ;
Zoukhri, Driss ;
Sullivan, David A. .
OCULAR SURFACE, 2017, 15 (03) :438-510
[5]   Acidic mammalian chitinase and the eye: implications for ocular inflammatory diseases [J].
Bucolo, Claudio ;
Musumeci, Maria ;
Musumeci, Salvatore ;
Drago, Filippo .
FRONTIERS IN PHARMACOLOGY, 2011, 2 :1-4
[6]  
Cáceres-del-Carpio J, 2016, DEV OPHTHALMOL, V55, P221, DOI 10.1159/000431198
[7]   Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype [J].
Cantarella, G. ;
Pignataro, G. ;
Di Benedetto, G. ;
Anzilotti, S. ;
Vinciguerra, A. ;
Cuomo, O. ;
Di Renzo, G. F. ;
Parenti, C. ;
Annunziato, L. ;
Bernardini, R. .
CELL DEATH & DISEASE, 2014, 5 :e1331-e1331
[8]   Comparative Evaluation of TRAIL, FGF-2 and VEGF-A-Induced Angiogenesis In Vitro and In Vivo [J].
Cartland, Sian P. ;
Genner, Scott W. ;
Zahoor, Amna ;
Kavurma, Mary M. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (12)
[9]   TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2-, Sp1 Phosphorylation-, and NFκB-Dependent Manner [J].
Chan, Jeffrey ;
Prado-Lourenco, Leonel ;
Khachigian, Levon M. ;
Bennett, Martin R. ;
Di Bartolo, Belinda A. ;
Kavurma, Mary M. .
CIRCULATION RESEARCH, 2010, 106 (06) :1061-1071
[10]   TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro [J].
Cholan, Pradeep Manuneedhi ;
Cartland, Sian P. ;
Dang, Lei ;
Rayner, Benjamin S. ;
Patel, Sanjay ;
Thomas, Shane R. ;
Kavurma, Mary M. .
FREE RADICAL BIOLOGY AND MEDICINE, 2018, 126 :341-349